Symbiotec Pharmalab IPO: Price Band, Dates, Key Details
Symbiotec Pharmalab IPO will open for public subscription on August 24, 2026, and close on August 27, 2026. The pharmaceutical company has set a price band of ₹938 to ₹988 per share and plans to raise around ₹1,757 crore at the upper end of the band.
The IPO includes both a fresh issue and an offer for sale (OFS). For retail investors, the minimum bid is 15 shares, which translates to an investment of ₹14,820 at the upper price band of ₹988 per share.
Symbiotec Pharmalab IPO details at a glance
| Particulars | Details |
|---|---|
| IPO opening date | August 24, 2026 |
| IPO closing date | August 27, 2026 |
| Price band | ₹938 to ₹988 per share |
| Issue size | Around ₹1,757 crore |
| Fresh issue | ₹150 crore |
| Offer for sale | Around ₹1,607 crore |
| Lot size | 15 shares |
| Minimum retail investment | ₹14,820 at ₹988 per share |
| Face value | ₹2 per share |
| Issue type | Book-built IPO |
| Listing exchanges | BSE and NSE |
| Tentative listing date | September 1, 2026 |
The final issue is reported to comprise approximately 1.78 crore equity shares, including a fresh issue of about 15.21 lakh shares and an OFS of roughly 1.63 crore shares.
What is the Symbiotec Pharmalab IPO price band?
The Symbiotec Pharmalab IPO price band is ₹938 to ₹988 per equity share. The shares have a face value of ₹2 each.
Retail investors can bid for a minimum of 15 shares and thereafter in multiples of 15 shares.
At the upper price of ₹988, the minimum application amount works out to:
15 shares × ₹988 = ₹14,820
A retail investor applying for 13 lots, or 195 shares, would invest ₹1,92,660 at the upper end of the price band.
What is the Symbiotec Pharmalab IPO issue size?
Symbiotec Pharmalab is looking to raise approximately ₹1,757 crore through the IPO at the upper end of the announced price band. The offer consists of two components:
- Fresh issue: ₹150 crore
- Offer for sale: Around ₹1,607 crore
This distinction matters for investors. Money raised through the fresh issue goes to the company, subject to issue expenses and the stated objects of the offer. Proceeds from the OFS go to the shareholders selling their existing shares.
The final IPO size is lower than the ₹2,180 crore offer initially proposed in the company’s draft papers, which comprised a ₹150 crore fresh issue and an OFS of up to ₹2,030 crore.
What are the important Symbiotec Pharmalab IPO dates?
The public issue will remain open for four days, from August 24 to August 27.
| IPO event | Date |
| Anchor investor bidding | August 21, 2026 |
| IPO opens | August 24, 2026 |
| IPO closes | August 27, 2026 |
| Tentative allotment | August 28, 2026 |
| Refunds initiated | August 31, 2026 |
| Shares credited to demat | August 31, 2026 |
| Tentative listing | September 1, 2026 |
Anchor investors are expected to be able to bid on August 21, ahead of the public issue.
The allotment and listing dates are tentative and may change. Investors should check the final exchange notices and registrar updates after the issue closes.
How will Symbiotec Pharmalab use the IPO proceeds?
Of the ₹150 crore fresh issue, Symbiotec Pharmalab plans to use ₹112.5 crore to prepay or repay certain outstanding borrowings. The remaining fresh issue proceeds are intended for general corporate purposes.
The company will not receive proceeds from the OFS component. Those funds will be paid to the respective selling shareholders after applicable offer expenses.
This is an important point when evaluating the IPO because the fresh capital available directly to the business represents a relatively small part of the overall offer.
What does Symbiotec Pharmalab do?
Symbiotec Pharmalab is a pharmaceutical and biotechnology company with operations spanning active pharmaceutical ingredients (APIs), contract development and manufacturing services, and complex injectables.
Its capabilities include organic chemistry, biotechnology and fermentation-based manufacturing. The company has a particularly strong presence in corticosteroid and steroidal-hormone APIs.
According to information disclosed around its draft filing, Symbiotec reported global volume market shares of 36.2% in corticosteroid APIs and 44.2% in steroidal-hormone APIs.
The company competes in an industry that includes listed Indian pharmaceutical companies such as Concord Biotech, Divi’s Laboratories, Cohance Lifesciences and Laurus Labs.
How has Symbiotec Pharmalab performed financially?
Symbiotec’s financial performance shows revenue growth, although profit growth has not been consistent every year.
According to the latest available IPO data, the company reported the following figures:
| Financial year | Revenue | Profit after tax |
| FY2024 | ₹716.25 crore | ₹100.06 crore |
| FY2025 | ₹751.55 crore | ₹96.79 crore |
| FY2026 | ₹869.15 crore | ₹109.90 crore |
FY2026 revenue increased to about ₹869.15 crore, while profit after tax rose to approximately ₹109.90 crore. Total borrowings stood at about ₹387.91 crore as of March 31, 2026, compared with ₹540.92 crore a year earlier.
Investors should still examine the final offer document for restated financial statements, cash flows, margins and any changes to the capital structure before making an investment decision.
What should investors check before applying?
The Symbiotec Pharmalab IPO gives investors exposure to a specialised pharmaceutical manufacturer with a significant position in steroid-related APIs. However, the business profile alone should not determine whether an IPO is attractive.
Before applying, investors may want to assess:
- Valuation: Compare the final IPO valuation with listed peers and the company’s earnings growth.
- OFS component: A large part of the ₹1,757 crore issue involves existing shareholders selling shares rather than fresh capital entering the company.
- Profitability: Revenue has grown, but investors should consider the consistency of profit and margin growth.
- Debt: Part of the fresh proceeds will be used to reduce borrowings.
- Business concentration: Review product, customer and geographic concentration risks in the final offer document.
- Regulatory exposure: Pharmaceutical manufacturing is subject to strict quality and regulatory requirements across domestic and international markets.
IPO subscription numbers and grey market premium, or GMP, can change quickly and should not be treated as substitutes for analysing the company’s fundamentals.
Is Symbiotec Pharmalab IPO listed on NSE and BSE?
Yes. Symbiotec Pharmalab’s equity shares are proposed to be listed on both the BSE and NSE. The tentative listing date is September 1, 2026.
MUFG Intime India Private Limited is identified as the registrar, while the book-running lead managers include JM Financial, Avendus Capital, Motilal Oswal Investment Advisors and Nomura Financial Advisory and Securities (India).
FAQs about Symbiotec Pharmalab IPO
Q. When will the Symbiotec Pharmalab IPO open?
The Symbiotec Pharmalab IPO will open for public subscription on August 24, 2026 and close on August 27, 2026.
Q. What is the Symbiotec Pharmalab IPO price band?
The price band is ₹938 to ₹988 per equity share.
Q. What is the lot size of the Symbiotec Pharmalab IPO?
The minimum lot size is 15 shares. Applications can be made in multiples of 15 shares.
Q. What is the minimum investment in the Symbiotec Pharmalab IPO?
At the upper price band of ₹988, one lot of 15 shares costs ₹14,820.
Q. What is the size of the Symbiotec Pharmalab IPO?
The company plans to raise approximately ₹1,757 crore at the upper end of the price band. This includes a ₹150 crore fresh issue and an OFS of around ₹1,607 crore.
Q. When is the Symbiotec Pharmalab IPO listing date?
The shares are tentatively expected to list on the BSE and NSE on September 1, 2026.
Q. What will Symbiotec Pharmalab do with the IPO money?
The company plans to use ₹112.5 crore from the fresh issue proceeds for repayment or prepayment of certain borrowings, with the balance earmarked for general corporate purposes. OFS proceeds will go to the selling shareholders.
Key takeaways
- Symbiotec Pharmalab IPO opens on August 24 and closes on August 27, 2026.
- The IPO price band is ₹938 to ₹988 per share.
- The total issue size is approximately ₹1,757 crore at the upper price band.
- The IPO includes a ₹150 crore fresh issue and an OFS of around ₹1,607 crore.
- The minimum lot is 15 shares, requiring ₹14,820 at the upper price.
- ₹112.5 crore of the fresh issue proceeds is planned for repayment or prepayment of borrowings.
- The shares are tentatively scheduled to list on BSE and NSE on September 1, 2026.
- Investors should evaluate valuation, financial performance, the large OFS component and business risks rather than relying only on subscription levels or GMP.
Disclaimer
The stocks mentioned in this article are not recommendations. Please conduct your own research and due diligence before investing. Investment in securities market are subject to market risks, read all the related documents carefully before investing. Please read the Risk Disclosure documents carefully before investing in Equity Shares, Derivatives, Mutual fund, and/or other instruments traded on the Stock Exchanges. As investments are subject to market risks and price fluctuation risk, there is no assurance or guarantee that the investment objectives shall be achieved. Lemonn (Formerly known as NU Investors Technologies Pvt. Ltd) do not guarantee any assured returns on any investments. Past performance of securities/instruments is not indicative of their future performance.
